Developed for type 2 diabetes mellitus to manage blood glucose and support glycemic stability.
Mechanism of Action
Linagliptin inhibits the DPP-4 enzyme to increase incretin hormone levels, which stimulates insulin release. Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity for a dual antidiabetic effect.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Severe renal impairment, Metabolic acidosis, Hypersensitivity to linagliptin or metformin
Severe Adverse Events
Lactic acidosis, Pancreatitis, Severe arthralgia — requires immediate medical attention
Information related to Jentadueto is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
